Abstract
Statins have become a mainstay therapy in cardiovascular and atherosclerotic disease. However, the use of statins in end stage kidney disease is a controversial topic. There is no evidence to support statins or other lipid lowering therapies in patients with end stage renal disease. This chapter seeks to review the epidemiology and risk factors of cardiovascular disease in the chronic kidney disease population, the literature and data regarding the beneficial and harmful effects of statins in this particular population and the international guidelines for their use. In addition, statins choices and doses in this population are reviewed.
| Original language | English (US) |
|---|---|
| Title of host publication | Lipid Management |
| Subtitle of host publication | From Basics to Clinic |
| Publisher | Springer International Publishing |
| Pages | 187-199 |
| Number of pages | 13 |
| ISBN (Electronic) | 9783319111612 |
| ISBN (Print) | 9783319111605 |
| DOIs | |
| State | Published - Jan 1 2015 |
| Externally published | Yes |
Bibliographical note
Publisher Copyright:© Springer International Publishing Switzerland 2015.
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Keywords
- Cardiovascular disease
- Chronic kidney disease
- Dialysis
- End stage renal disease
- Glomerular filtration rate
- Statins
Fingerprint
Dive into the research topics of 'Statins in chronic kidney disease'. Together they form a unique fingerprint.Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS